Next 10 |
home / stock / invvy / invvy news
Indivior Announces Q1 2024 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va. , April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024 . The earnings re...
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone PR Newswire This head-to-head pharmacodynamic study in healthy volunteers...
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation PR Newswire RICHMOND, Va. , Feb. 29, 2024 /PRNewswire/ -- Indivior PLC (LSE: I...
2023-11-11 09:39:05 ET Indivior PLC (INVVY) Q3 2023 Earnings Conference Call November 9, 2023, 8:00 a.m. ET Company Participants Mark Crossley - CEO Ryan Preblick - CFO Dr. Christian Heidbreder - Chief Scientific Officer Jason Thompson - VP, IR Conferen...
Indivior Announces Q3 2023 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va. , Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023 . The earnings ...
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals PR Newswire - Alar's Lead Asset ALA-1000 Potentially is the First Three-Month LAI Treatment for OUD - RICHMOND, Va. , Oct. 11, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: ...
Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada PR Newswire Rates of non-fatal overdose events following SUBLOCADE treatment was lower compared to daily opioid agonist therapy. ...
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims PR Newswire RICHMOND, Va. , Aug. 21, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, announced that its subsid...
2023-07-29 04:50:08 ET Indivior PLC (INVVY) Q2 2023 Earnings Conference Call July 27, 2023, 08:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Offi...
2023-07-27 06:00:37 ET Indivior PLC ADR press release ( OTCPK:INVVY ): Q2 Non-GAAP EPS of $0.39. Revenue of $276M (+24.9% Y/Y). For further details see: Indivior PLC ADR Non-GAAP EPS of $0.39, revenue of $276M
News, Short Squeeze, Breakout and More Instantly...
Indivior PLC ADR Company Name:
INVVY Stock Symbol:
OTCMKTS Market:
Indivior Announces Q1 2024 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va. , April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024 . The earnings re...
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone PR Newswire This head-to-head pharmacodynamic study in healthy volunteers...
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation PR Newswire RICHMOND, Va. , Feb. 29, 2024 /PRNewswire/ -- Indivior PLC (LSE: I...